Bradley Augustson

1.5k total citations
43 papers, 684 citations indexed

About

Bradley Augustson is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Bradley Augustson has authored 43 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Hematology, 15 papers in Genetics and 15 papers in Oncology. Recurrent topics in Bradley Augustson's work include Multiple Myeloma Research and Treatments (31 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Protein Degradation and Inhibitors (8 papers). Bradley Augustson is often cited by papers focused on Multiple Myeloma Research and Treatments (31 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Protein Degradation and Inhibitors (8 papers). Bradley Augustson collaborates with scholars based in Australia, United States and United Kingdom. Bradley Augustson's co-authors include Janet Dunn, Gareth J. Morgan, Mark T. Drayson, J. A. Child, Alastair G. Smith, Judith Behrens, Faith E. Davies, Gulnaz Begum, Hang Quach and Andrew Spencer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Bradley Augustson

36 papers receiving 669 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bradley Augustson Australia 11 502 312 282 186 127 43 684
Howard R. Terebelo United States 14 473 0.9× 309 1.0× 312 1.1× 129 0.7× 61 0.5× 74 716
Brian McClune United States 15 750 1.5× 323 1.0× 213 0.8× 121 0.7× 66 0.5× 68 998
Paola Masolini Italy 17 389 0.8× 294 0.9× 252 0.9× 187 1.0× 110 0.9× 24 849
Antònia Sampol Spain 14 430 0.9× 189 0.6× 117 0.4× 153 0.8× 147 1.2× 60 731
Yeow Tee Goh Singapore 16 501 1.0× 218 0.7× 243 0.9× 367 2.0× 142 1.1× 101 932
Andrew Belch United States 15 839 1.7× 535 1.7× 425 1.5× 239 1.3× 138 1.1× 32 1.1k
Miguel‐Teodoro Hernández Spain 14 796 1.6× 544 1.7× 597 2.1× 210 1.1× 165 1.3× 44 1.2k
S. Faderl United States 16 882 1.8× 240 0.8× 417 1.5× 393 2.1× 97 0.8× 24 1.2k
Susana Vives Spain 10 533 1.1× 209 0.7× 272 1.0× 152 0.8× 66 0.5× 37 791
Roberto Sorasio Italy 14 542 1.1× 291 0.9× 286 1.0× 83 0.4× 210 1.7× 33 853

Countries citing papers authored by Bradley Augustson

Since Specialization
Citations

This map shows the geographic impact of Bradley Augustson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bradley Augustson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bradley Augustson more than expected).

Fields of papers citing papers by Bradley Augustson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bradley Augustson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bradley Augustson. The network helps show where Bradley Augustson may publish in the future.

Co-authorship network of co-authors of Bradley Augustson

This figure shows the co-authorship network connecting the top 25 collaborators of Bradley Augustson. A scholar is included among the top collaborators of Bradley Augustson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bradley Augustson. Bradley Augustson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vandyke, Kate, Bradley Augustson, Georgia McCaughan, et al.. (2025). Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia. Expert Review of Hematology. 19(2). 133–142.
2.
3.
Petrie, Dennis, Anthony Harris, Laura Fanning, et al.. (2024). Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLoS ONE. 19(8). e0308812–e0308812.
4.
5.
Wellard, Cameron, Elizabeth S. Moore, Bradley Augustson, et al.. (2024). Integrating Chromosomal 1 Abnormalities into the Definition of High-Risk Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry. Blood. 144(Supplement 1). 1951–1951. 1 indexed citations
6.
Augustson, Bradley, Hira Mian, Edward A. Stadtmauer, et al.. (2024). A Phase I/II Study of AZD0305, a Novel Antibody-Drug Conjugate (ADC) Targeting GPRC5D, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 2000.2–2000.2. 1 indexed citations
7.
Popat, Rakesh, Bradley Augustson, Mercedes Gironella, et al.. (2023). Belantamab Mafodotin in Combination with Lenalidomide Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Analysis of DREAMM-6 Trial Arm-a. Blood. 142(Supplement 1). 2010–2010. 2 indexed citations
8.
Talaulikar, Dipti, Douglas Joshua, John Gibson, et al.. (2022). Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Internal Medicine Journal. 53(4). 599–609. 1 indexed citations
9.
Bergin, Krystal, Cameron Wellard, Bradley Augustson, et al.. (2021). Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation. 56(10). 2533–2543. 9 indexed citations
10.
Fuller, Kathryn A., et al.. (2020). Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma. Journal of Clinical Pathology. 75(1). 50–57. 1 indexed citations
11.
Barraclough, Allison, Musa Alzahrani, Mark Bishton, et al.. (2019). COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances. 3(13). 2013–2021. 28 indexed citations
12.
Ho, P. Joy, Elizabeth Moore, Zoe McQuilten, et al.. (2019). Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. Clinical Lymphoma Myeloma & Leukemia. 19(8). e415–e424. 17 indexed citations
13.
Lane, Heather, et al.. (2018). ‘It is a journey of discovery’: living with myeloma. Supportive Care in Cancer. 27(7). 2435–2442. 7 indexed citations
14.
Byrd, John C., Stephen D. Smith, Nina D. Wagner‐Johnston, et al.. (2018). First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 9(16). 13023–13035. 67 indexed citations
15.
16.
Bergin, Krystal, Elizabeth Moore, Zoe McQuilten, et al.. (2016). Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. BMC Medical Research Methodology. 16(1). 151–151. 22 indexed citations
17.
Viecelli, Andrea K., et al.. (2014). Diagnostic and management dilemma of a pancreas–kidney transplant recipient with aplastic anaemia. BMJ Case Reports. 2014. bcr2014205076–bcr2014205076.
18.
Ishak, K. Jack, J. Jaime, Mark T. Drayson, et al.. (2011). Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma. Value in Health. 14(5). 672–678. 8 indexed citations
19.
Ghassemifar, Reza, Christine B.F. Thien, David Joske, et al.. (2011). Incidence of c-Cbl mutations in human acute myeloid leukaemias in an Australian patient cohort. Pathology. 43(3). 261–265. 3 indexed citations
20.
Thin, Lena, Gerry MacQuillan, Leon A. Adams, et al.. (2009). Acute graft-versus-host disease after liver transplant: Novel use of etanercept and the role of tumor necrosis factor α inhibitors. Liver Transplantation. 15(4). 421–426. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard R. Terebelo Breakdown of academic impact, for papers by Brian McClune Breakdown of academic impact, for papers by Paola Masolini Breakdown of academic impact, for papers by Antònia Sampol Breakdown of academic impact, for papers by Yeow Tee Goh Breakdown of academic impact, for papers by Andrew Belch Breakdown of academic impact, for papers by Miguel‐Teodoro Hernández Breakdown of academic impact, for papers by S. Faderl Breakdown of academic impact, for papers by Susana Vives Breakdown of academic impact, for papers by Roberto Sorasio
Rankless by CCL
2026